The multi-center, open-label study is expected to enroll approximately 100 subjects with metastatic pancreatic cancer who have failed prior chemotherapy. Subjects are to receive daily oral monotherapy with Tyme's investigational drug therapy, SM-88.

In March 2018, Tyme announced the commencement of the trial. Up to thirty-five trial sites across the United States are expected to participate in the study.

Additional information regarding the trial are expected to be listed on www.clinicaltrials.gov soon. In the interim if you have questions related to this trial you can contact clinical@tymeinc.com.